nhf_4c     mer        10th annynoanny ie logo_large
Post-Activity Survey and Evaluation
The Promise of Gene Therapy: Access and Coverage for Innovative, High-Cost Treatments
 
QP
In an effort to better determine the overall effectiveness of continuing education activities, we are conducting a brief survey. Listed below are questions for which we would like your responses. All information obtained will be used and reported in aggregate only, without individual attribution. Thank you for your participation.

If you have any questions please contact us at info@impactedu.net.

*All questions are required.
Q1.1 Now that you have participated in this activity, how confident are you in your ability to distinguish innovative approaches that have been proposed for the funding and coverage of emerging high-cost therapies?
 
Q1.2 What conditions represent the second leading disease area (i.e., other than cancer) in terms of gene therapy research and development?
 
Q1.3 Which potential strategy for the funding and coverage of gene therapy is a specialized approach that allows for more effective and efficient care?
 
Q1.4 Now that you have participated in this activity, how confident are you in your ability to evaluate results from gene therapy trials for the treatment of hemophilia?
 
Q1.5 Within your plan or practice setting when applicable, how often do you plan to consider your current organizationís environment and characteristics when assessing innovative access schemes for gene therapies?    (1 = Never, 6 = Always)
(Please select the appropriate number on the scale below or mark if this decision or authority is outside your usual scope of practice)  
 
Evaluation Form

Medical Education Resources, Inc. is committed to excellence in continuing education, and your opinions are critical to us in this effort.  To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form.

You must complete this evaluation form to receive acknowledgment for completing this activity.
Q1.6 What is your specialty?
 
  Q1.6a. Please explain "other".
Q1.7 What best describes your primary role?
 
 
 
 
 
 
 
 
 
 
 
   
  Q1.7a. Please explain "other".
Q1.8 How many years have you been in your area of responsibility?
 
Q1.9 Approximately how many patients with hemophilia are being managed in your organization, practice setting, or affiliated organizations?
 
Q1.10 Rate how well the activity supported your achievement of these learning objectives.
           
  Describe the molecular and physiologic principles of gene therapy in the treatment of hemophilia          
  Review outcomes measures for clinical trials in hemophilia gene therapy and the pertinent clinical trial data for investigational treatments          
  Characterize the financial implications of gene therapy in terms of acquisition costs reconciled with the potential for improved outcomes and reduced health care service utilization          
  Outline current and proposed payment models aligned with appropriate use for high-cost therapies          
Q1.11 Please select the extent to which you agree/disagree that the speakers achieved the following:
Effective in Presenting the Material
           
  Edmund Pezalla, MD, MPH          
  Tammuella Chrisentery-Singleton, MD          
  Mary-Pat Pusey, MBA          
  Brendan Hayes          
Q1.12 Please select the extent to which you agree/disagree that the speakers achieved the following:
Avoided Commercial Bias or Influence
           
  Edmund Pezalla, MD, MPH          
  Tammuella Chrisentery-Singleton, MD          
  Mary-Pat Pusey, MBA          
  Brendan Hayes          
Q1.13 Rate how well the activity achieved the following.
           
  The content was evidence based          
  The educational material provided useful information for my practice          
  The activity enhanced my current knowledge base          
  The activity provided appropriate and effective opportunities for active learning (eg, case studies, discussion, Q&A, etc)          
  The opportunities provided to assess my own learning were appropriate (eg, questions before, during or after the activity)          
Q1.14 Based upon your participation in this activity, do you intend to change your practice and/or administrative behavior?
 
 
Q1.15
Q1.16 If you plan to change your practice and/or administrative behavior, what type of changes do you plan to implement?
(check all that apply)
 
 
  Q1.17o. Please specify "other".
Q1.17 How confident are you that you will be able to make your intended changes?
 
 
Q1.18 Which of the following do you anticipate will be the primary barrier to implementing these changes?
 
 
  Q1.19o. Please specify "other".
Q1.19 Was the content of this activity fair, balanced, objective, and free of commercial bias?
 
 
  Q1.19o. Please explain.
Q1.20
Q1.21
Q1.22
Q1.23
Q1.24
Q1.25
Q1.26
Q1.27
Q1.28
Q1.29 Type of Credit
 
Q1.30
Q1.31 TO CLAIM CREDIT: Upon submission of your evaluation you will be redirected to a web page with instructions. You must follow the instructions to claim credit. Submission of the evaluation alone will not provide credit.
 
 


If you have any questions please email info@impactedu.net.